Scientists at Nanyang Technological University (NTU) have identified a gut protein called angiopoietin-like 4 that acts as a primary indicator for fatty liver disease. By analyzing stool samples, researchers found that elevated levels of this protein correlate with a “leaky gut,” a condition that allows inflammatory bacteria to travel to the liver. Published in Nature Communications on May 22, this discovery offers a non-invasive diagnostic alternative to traditional blood tests for detecting early-stage liver damage.
How does the gut-liver connection impact disease?
The damage associated with fatty liver often begins in the digestive tract rather than the liver itself. According to Damien Chua, a doctorate student at LKCMedicine and principal investigator, the gut becomes overly porous, allowing bacteria to migrate directly to the liver. This migration triggers inflammation and the subsequent build-up of fat. This shift in understanding suggests that current diagnostic methods, which rely heavily on blood-based liver enzyme markers, may miss early-stage warning signs. Chua notes that these blood markers often fail to align with the actual progression of gut-related liver damage.
Local projections from the Annals of the Academy of Medicine, Singapore, estimate that the burden of non-alcoholic fatty liver disease in Singapore will climb from 1.49 million cases in 2019 to 1.8 million by 2030.
Why are stool samples more effective for diagnosis?
Stool samples provide a more direct window into gut health than blood tests. Associate Professor Andrew Tan, who headed the study at LKCMedicine, explains that while blood tests are standard, they are not always robust enough to catch the onset of fatty liver. The research team utilized stool samples from patient cohorts across Singapore, Thailand, China, and India to validate the protein as a consistent biomarker. Because the test can be performed using standard PCR machines already present in clinical laboratories, researchers believe it could be integrated into existing diagnostic workflows with relative ease.
Can this test be integrated into public health programs?
Researchers are exploring how to incorporate this biomarker test into national initiatives like Healthier SG. According to Tan, the goal is to shift from reactive medical treatments to proactive, preventive care. The current Healthier SG protocol already utilizes the faecal immunochemical test (FIT) to screen for colorectal cancer. By leveraging this existing infrastructure, clinicians could potentially add the protein biomarker test to the same stool sample, providing a more comprehensive health assessment without requiring multiple invasive procedures.
Future developments in liver diagnostics
- Microfluidic devices: NTU engineering teams are currently developing a microfluidic version of the test to allow for faster, more portable diagnostics.
- Cross-border validation: The research team is collaborating with institutions in China and Thailand to measure protein levels before and after clinical treatments.
- Complementary screening: The test is intended to work alongside genetic risk assessments, such as those recently identified by the National University Hospital (NUH), to provide a multi-faceted view of liver cancer risks.
Early intervention is critical for fatty liver disease, as many patients remain asymptomatic. If you are concerned about your metabolic health, discuss non-invasive screening options with your primary care provider during your next check-up.
Frequently Asked Questions
What is a “leaky gut”?
A leaky gut occurs when the intestinal lining becomes overly porous, allowing bacteria and toxins to escape the gut and enter the bloodstream, potentially reaching the liver and triggering inflammation.
Why is this test better than a blood test?
According to the NTU research team, blood markers for fatty liver are often unreliable because they do not reflect the early-stage gut changes that precede liver fat accumulation.
Is this test currently available?
The test is currently in the research and development phase. Scientists are working to streamline it for routine clinical use within existing diagnostic frameworks.
Have you or a family member participated in metabolic health screenings? Share your experience in the comments below or subscribe to our newsletter for more updates on medical breakthroughs.
